AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
10.05.2022 - On Track for Several Milestones in 2022, and Supported by Strong Balance Sheet from Upsized Initial Public Offering Continued Progress Advancing Epetraborole Clinical Program with Enrollment for Pivotal Phase 2/3 Trial in Treatment-Refractory MAC ...
Source: wallstreet-online.de